Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination.

Hammerich L, Marron TU, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S, Zhan Y, Ostrowski D, Yellin M, Marsh H, Salazar AM, Rahman AH, Brown BD, Merad M, Brody JD.

Nat Med. 2019 May;25(5):814-824. doi: 10.1038/s41591-019-0410-x. Epub 2019 Apr 8.

PMID:
30962585
2.

Flt3L Treatment of Bone Marrow Donors Increases Graft Plasmacytoid Dendritic Cell Content and Improves Allogeneic Transplantation Outcomes.

Hassan M, Ulezko Antonova A, Li JM, Hosoba S, Rupji M, Kowalski J, Perricone AJ, Jaye DL, Marsh H, Yellin M, Devine S, Waller EK.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1075-1084. doi: 10.1016/j.bbmt.2018.11.029. Epub 2018 Nov 29.

PMID:
30503387
3.

Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH.

Lancet Oncol. 2017 Dec;18(12):e709-e710. doi: 10.1016/S1470-2045(17)30856-2. No abstract available.

PMID:
29208433
4.

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT IV trial investigators.

Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23.

5.

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.

Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE 3rd, Hawthorne TR, Davis TA, Yellin MJ, Keler T, Bullock T.

J Clin Oncol. 2017 Jun 20;35(18):2028-2036. doi: 10.1200/JCO.2016.70.1508. Epub 2017 May 2. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):359.

PMID:
28463630
6.

Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers.

Anandasabapathy N, Breton G, Hurley A, Caskey M, Trumpfheller C, Sarma P, Pring J, Pack M, Buckley N, Matei I, Lyden D, Green J, Hawthorne T, Marsh HC, Yellin M, Davis T, Keler T, Schlesinger SJ.

Bone Marrow Transplant. 2015 Jul;50(7):924-30. doi: 10.1038/bmt.2015.74. Epub 2015 Apr 27.

7.

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, Cigler T, Stopeck A, Citrin D, Oliff I, Bechhold R, Loutfi R, Garcia AA, Cruickshank S, Crowley E, Green J, Hawthorne T, Yellin MJ, Davis TA, Vahdat LT.

J Clin Oncol. 2015 May 10;33(14):1609-19. doi: 10.1200/JCO.2014.56.2959. Epub 2015 Apr 6.

PMID:
25847941
8.

Animal-assisted therapy with chronic psychiatric inpatients: equine-assisted psychotherapy and aggressive behavior.

Nurenberg JR, Schleifer SJ, Shaffer TM, Yellin M, Desai PJ, Amin R, Bouchard A, Montalvo C.

Psychiatr Serv. 2015 Jan 1;66(1):80-6. doi: 10.1176/appi.ps.201300524. Epub 2014 Oct 31.

PMID:
25269512
9.

Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.

Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, Kluger H, Tejwani S, Green J, Ramakrishna V, Crocker A, Vitale L, Yellin M, Davis T, Keler T.

Sci Transl Med. 2014 Apr 16;6(232):232ra51. doi: 10.1126/scitranslmed.3008068.

10.

Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.

Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S, Aranda R, Luo AY.

Gut. 2014 Mar;63(3):442-50. doi: 10.1136/gutjnl-2012-303424. Epub 2013 Mar 5.

11.

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis.

Yellin M, Paliienko I, Balanescu A, Ter-Vartanian S, Tseluyko V, Xu LA, Tao X, Cardarelli PM, Leblanc H, Nichol G, Ancuta C, Chirieac R, Luo A.

Arthritis Rheum. 2012 Jun;64(6):1730-9. doi: 10.1002/art.34330. Epub 2011 Dec 6.

12.

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma.

Sarnaik AA, Yu B, Yu D, Morelli D, Hall M, Bogle D, Yan L, Targan S, Solomon J, Nichol G, Yellin M, Weber JS.

Clin Cancer Res. 2011 Feb 15;17(4):896-906. doi: 10.1158/1078-0432.CCR-10-2463. Epub 2010 Nov 24.

13.

Improved survival with ipilimumab in patients with metastatic melanoma.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ.

N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.

14.

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.

Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS.

Invest New Drugs. 2011 Jun;29(3):489-98. doi: 10.1007/s10637-009-9376-8. Epub 2010 Jan 16.

PMID:
20082117
15.

Phase I/II study of ipilimumab for patients with metastatic melanoma.

Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E.

J Clin Oncol. 2008 Dec 20;26(36):5950-6. doi: 10.1200/JCO.2008.16.1927. Epub 2008 Nov 17.

PMID:
19018089
16.

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8. Epub 2007 Nov 2.

17.

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, Keler T, Graziano R, Blanset D, Yellin M, Fischkoff S, Assad A, Borchmann P.

J Clin Oncol. 2007 Jul 1;25(19):2764-9. Epub 2007 May 21.

PMID:
17515574
18.

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma.

Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P, Rosenberg SA.

J Immunother. 2006 Jul-Aug;29(4):455-63.

19.

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC.

J Clin Oncol. 2006 May 20;24(15):2283-9.

20.

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.

Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA.

Ann Surg Oncol. 2005 Dec;12(12):1005-16. Epub 2005 Oct 21.

21.

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA.

J Clin Oncol. 2005 Sep 1;23(25):6043-53. Epub 2005 Aug 8.

22.

Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.

Korman A, Yellin M, Keler T.

Curr Opin Investig Drugs. 2005 Jun;6(6):582-91. Review.

PMID:
15988909
23.

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.

Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J.

J Clin Oncol. 2005 Feb 1;23(4):741-50. Epub 2004 Dec 21.

PMID:
15613700
24.

CD40 ligation triggers COX-2 expression in endothelial cells: evidence that CD40-mediated IL-6 synthesis is COX-2-dependent.

Dongari-Bagtzoglou AI, Thienel U, Yellin MJ.

Inflamm Res. 2003 Jan;52(1):18-25.

PMID:
12608645
25.

Suppression of murine cardiac allograft arteriopathy by long-term blockade of CD40-CD154 interactions.

Wang CY, Mazer SP, Minamoto K, Takuma S, Homma S, Yellin M, Chess L, Fard A, Kalled SL, Oz MC, Pinsky DJ.

Circulation. 2002 Apr 2;105(13):1609-14.

PMID:
11927531
26.
27.

A case of Susac syndrome.

Yellin MW, Johnson TW.

J Am Acad Audiol. 2000 Oct;11(9):484-8.

PMID:
11057732
28.

Analysis of CD154 and CD40 expression in native coronary atherosclerosis and transplant associated coronary artery disease.

Szabolcs MJ, Cannon PJ, Thienel U, Chen R, Michler RE, Chess L, Yellin MJ.

Virchows Arch. 2000 Aug;437(2):149-59.

PMID:
10993275
29.

Otoacoustic emissions in normal-cycling females.

Yellin MW, Stillman RD.

J Am Acad Audiol. 1999 Jul-Aug;10(7):400-8.

PMID:
10949944
30.

CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets.

Thienel U, Loike J, Yellin MJ.

Cell Immunol. 1999 Dec 15;198(2):87-95.

PMID:
10648122
31.

Fat embolism and hemorrhagic lupus pneumonitis in a patient with systemic lupus erythematosus.

Thienel U, Yellin M, Blume R.

J Rheumatol. 1999 Aug;26(8):1849. No abstract available.

PMID:
10451091
32.
33.
34.

CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression.

Miller DL, Yaron R, Yellin MJ.

J Leukoc Biol. 1998 Mar;63(3):373-9.

PMID:
9500526
35.

Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides.

Yellin MJ, D'Agati V, Parkinson G, Han AS, Szema A, Baum D, Estes D, Szabolcs M, Chess L.

Arthritis Rheum. 1997 Jan;40(1):124-34.

PMID:
9008608
37.

The central role of the CD40-ligand and CD40 pathway in T-lymphocyte-mediated differentiation of B lymphocytes.

Lederman S, Cleary AM, Yellin MJ, Frank DM, Karpusas M, Thomas DW, Chess L.

Curr Opin Hematol. 1996 Jan;3(1):77-86. Review.

PMID:
9372055
38.

Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals.

Yellin MJ, Brett J, Baum D, Matsushima A, Szabolcs M, Stern D, Chess L.

J Exp Med. 1995 Dec 1;182(6):1857-64.

39.

Opposing roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human low density tonsillar B cells.

Cleary AM, Fortune SM, Yellin MJ, Chess L, Lederman S.

J Immunol. 1995 Oct 1;155(7):3329-37.

PMID:
7561026
40.

Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation.

Yellin MJ, Winikoff S, Fortune SM, Baum D, Crow MK, Lederman S, Chess L.

J Leukoc Biol. 1995 Aug;58(2):209-16.

PMID:
7543921
41.

Simultaneous comparison between transtympanic and extratympanic electrocochleography.

Roland PS, Yellin MW, Meyerhoff WL, Frank T.

Am J Otol. 1995 Jul;16(4):444-50.

PMID:
8588643
42.

Phenotypic and functional characterization of T-BAM (CD40 ligand)+ T-cell non-Hodgkin's lymphoma.

Inghirami G, Lederman S, Yellin MJ, Chadburn A, Chess L, Knowles DM.

Blood. 1994 Aug 1;84(3):866-72.

43.

T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity.

Yellin MJ, Sinning J, Covey LR, Sherman W, Lee JJ, Glickman-Nir E, Sippel KC, Rogers J, Cleary AM, Parker M, et al.

J Immunol. 1994 Jul 15;153(2):666-74.

PMID:
7517421
44.

Isolation of cDNAs encoding T-BAM, a surface glycoprotein on CD4+ T cells mediating contact-dependent helper function for B cells: identity with the CD40-ligand.

Covey LR, Cleary AM, Yellin MJ, Ware R, Sullivan G, Belko J, Parker M, Rothman P, Chess L, Lederman S.

Mol Immunol. 1994 Apr;31(6):471-84.

PMID:
7514269
45.

T-BAM/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death.

Lederman S, Yellin MJ, Cleary AM, Pernis A, Inghirami G, Cohn LE, Covey LR, Lee JJ, Rothman P, Chess L.

J Immunol. 1994 Mar 1;152(5):2163-71.

PMID:
7907632
46.

The understanding of contact-dependent T-cell helper function in molecular, cellular and physiological detail.

Lederman S, Yellin MJ, Cleary AM, Fortune SM, Chess L.

Res Immunol. 1994 Mar-Apr;145(3):215-21; discussion 244-9. Review. No abstract available.

PMID:
7527578
47.

CD40 molecules induce down-modulation and endocytosis of T cell surface T cell-B cell activating molecule/CD40-L. Potential role in regulating helper effector function.

Yellin MJ, Sippel K, Inghirami G, Covey LR, Lee JJ, Sinning J, Clark EA, Chess L, Lederman S.

J Immunol. 1994 Jan 15;152(2):598-608.

PMID:
7506727
48.

Dehydration testing and the diagnosis of Menière's disease: case report.

Yellin MW, Waller M, Roland PS.

J Am Acad Audiol. 1993 Nov;4(6):432-6.

PMID:
8298180
49.

Deletions in the ligand for CD40 in X-linked immunoglobulin deficiency with normal or elevated IgM (HIGMX-1).

Ramesh N, Fuleihan R, Ramesh V, Lederman S, Yellin MJ, Sharma S, Chess L, Rosen FS, Geha RS.

Int Immunol. 1993 Jul;5(7):769-73.

PMID:
8103673
50.

Non-antigen signals for B-cell growth and differentiation to antibody secretion.

Lederman S, Yellin MJ, Covey LR, Cleary AM, Callard R, Chess L.

Curr Opin Immunol. 1993 Jun;5(3):439-44. Review.

PMID:
7688518

Supplemental Content

Loading ...
Support Center